Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib added to letrozole in hormone-refractory ER-positive metastatic breast cancer
2006-002814-37Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in breast cancer, sponsored by Boehringer Ingelheim. Primary endpoint: Progression-free rate at 16 weeks. Started Aug 2006; status: completed.
02
Drugs
afatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-002814-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002814-37.